n°264

November 2024

Issue Contents
Editorial

Free  European pharmaceutical legislation: too many opportunities missed

p.255

Marketing Authorisations


Tirzepatide (Mounjaro°) in type 2 diabetes

p.257-259

Herpes zoster vaccine gE/AS01B (Shingrix°)

p.260-263

Risankizumab (Skyrizi°) in Crohn's disease after failure of at least one other immunosuppressant

p.264

Ibrutinib (Imbruvica°) in combination with venetoclax as first-line therapy for chronic lymphocytic leukaemia

p.265-266

Nivolumab + relatlimab (Opdualag°) as first-line therapy for inoperable or metastatic melanoma

p.266

Sacituzumab govitecan (Trodelvy°) in metastatic hormone receptor-positive breast cancer, after failure of several treatments

p.267

Tabelecleucel (Ebvallo°) in Epstein-Barr virus-associated lymphoproliferative disease following a transplant

p.268-269

Emicizumab (Hemlibra°) in moderate haemophilia A with a risk of severe bleeding

p.269

Ravulizumab (Ultomiris°) in neuromyelitis optica spectrum disorder

p.269-270

Upadacitinib (Rinvoq°) in Crohn's disease

p.270

Relugolix (Orgovyx°) in "advanced" hormone-sensitive prostate cancer

p.271

Tirzepatide in obesity: not shown to represent a therapeutic advance over semaglutide as of mid-2024

p.272

Adverse Effects


TNF-alpha inhibitors: manic episodes?

p.273-274

Antimuscarinic drugs: cardiovascular disorders

p.274

Hormonal contraception + NSAIDs: deep vein thrombosis and pulmonary embolism

p.275

Minoxidil: hypertrichosis in a 4-month-old infant

p.275

Gabapentin, pregabalin: COPD exacerbation

p.276

Tianeptine: abuse and dependence (continued)

p.276

Inhaled antimuscarinic drugs: mental health disorders

p.277

Common stem: estr-, -estr-

p.277

Outlook


Free  Revision of European pharmaceutical legislation: a disappointing vote in the Parliament

p.278-279

Free  French Senate hearing on drug shortages

p.279

Masthead


Free  Masthead

p.254

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe